MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mineralys Therapeutics Inc (MLYS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive catalysts such as strong clinical trial results, FDA review progress, and hedge fund interest. Despite the current bearish technical indicators, the long-term potential of its blockbuster drug lorundrostat in a $5B market and positive analyst ratings make it a compelling investment opportunity.
The technical indicators for MLYS are currently bearish. The MACD histogram is negative and contracting, RSI is neutral at 46.931, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 24.075, R1: 25.485, S1: 22.666, R2: 26.356, S2: 21.795.
Positive clinical trial data showing lorundrostat reduces heart failure risk biomarkers.
FDA review in progress with a decision expected by December 22,
Hedge funds are significantly increasing their positions in the stock (516.79% increase in buying over the last quarter).
Analysts highlight lorundrostat's blockbuster potential in a $5B market with favorable pricing and better labeling compared to competitors.
Current bearish technical indicators.
Recent price decline of -1.99% in the regular market and -0.72% in pre-market trading.
No recent insider or congress trading activity to provide additional confidence.
No financial data available for the latest quarter, so growth trends cannot be assessed.
Analysts are bullish on MLYS. Goldman Sachs recently lowered the price target from $49 to $42 but maintained a Buy rating. TD Cowen initiated coverage with a Buy rating, citing lorundrostat's blockbuster potential in a $5B market.
